Kineta Reports Initial Clinical Response Data at AACR 2024
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety...
Source: globenewswire.com
Page 11 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Merck Sharp Today - Breaking & Trending Today
Moderna : AACR INT Head & Neck Poster -April 08, 2024 at 04:52 pm EDT
CT141 mRNA-4157 Individualized Neoantigen Therapy +...
Source: marketscreener.com
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer. Patients will b
Source: yahoo.com
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27,
INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the...
Source: globenewswire.com